Metropolitan Life Insurance CO Vaxcyte, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$59.79 - $81.05 $15,067 - $20,424	252 Added 4.74%	5,573 $380,000
Q4 2023 Feb 14, 2024	SELL	$45.35 - $63.41 $5,305 - $7,418	-117 Reduced 2.15%	5,321 $334,000
Q3 2023 Nov 14, 2023	BUY	$46.0 - $53.1 $19,228 - $22,195	418 Added 8.33%	5,438 $277,000
Q2 2023 Aug 10, 2023	BUY	$34.66 - $54.07 $36,115 - $56,340	1,042 Added 26.19%	5,020 $250,000
Q1 2023 May 15, 2023	SELL	$36.27 - $47.2 $16,430 - $21,381	-453 Reduced 10.22%	3,978 $149,000
Q4 2022 Jun 14, 2023	BUY	$20.58 - $47.95 $9,322 - $21,721	453 Added 11.39%	4,431 $212 Million
Q4 2022 Mar 30, 2023	BUY	$20.58 - $47.95 $25,457 - $59,314	1,237 Added 38.73%	4,431 $212,000
Q4 2022 Feb 15, 2023	BUY	$20.58 - $47.95 $25,457 - $59,314	1,237 Added 38.73%	4,431 $212,000
Q3 2022 Jun 14, 2023	SELL	$21.69 - $28.53 $17,004 - $22,367	-784 Reduced 19.71%	3,194 $76.7 Million
Q2 2022 Jun 20, 2023	SELL	$17.68 - $26.58 $13,861 - $20,838	-784 Reduced 19.71%	3,194 $69,000
Q2 2022 Mar 30, 2023	BUY	$17.68 - $26.58 $9,193 - $13,821	520 Added 19.45%	3,194 $69,000
Q2 2022 Aug 11, 2022	BUY	$17.68 - $26.58 $9,193 - $13,821	520 Added 19.45%	3,194 $70,000
Q1 2022 Jun 20, 2023	SELL	$17.46 - $26.36 $22,767 - $34,373	-1,304 Reduced 32.78%	2,674 $64,000
Q1 2022 Mar 30, 2023	SELL	$17.46 - $26.36 $152,652 - $230,465	-8,743 Reduced 76.58%	2,674 $64,000
Q1 2022 May 12, 2022	SELL	$17.46 - $26.36 $152,652 - $230,465	-8,743 Reduced 76.58%	2,674 $65,000
Q4 2021 Jun 21, 2023	BUY	$19.32 - $26.45 $143,721 - $196,761	7,439 Added 187.0%	11,417 $271,000
Q3 2021 Jun 21, 2023	BUY	$20.26 - $26.97 $150,714 - $200,629	7,439 Added 187.0%	11,417 $289,000
Q2 2021 Jun 21, 2023	BUY	$16.45 - $24.06 $122,371 - $178,982	7,439 Added 187.0%	11,417 $256,000
Q2 2021 Mar 30, 2023	BUY	$16.45 - $24.06 $47,063 - $68,835	2,861 Added 33.44%	11,417 $256,000
Q2 2021 Aug 16, 2021	BUY	$16.45 - $24.06 $187,661 - $274,476	11,408 Added 126755.56%	11,417 $257,000
Q1 2021 Jun 26, 2023	BUY	$18.66 - $29.16 $85,425 - $133,494	4,578 Added 115.08%	8,556 $169 Million
Q1 2021 Mar 30, 2023	BUY	$18.66 - $29.16 $58,946 - $92,116	3,159 Added 58.53%	8,556 $168,000
Q1 2021 May 14, 2021	SELL	$18.66 - $29.16 $100,540 - $157,114	-5,388 Reduced 99.83%	9 $169,000
Q4 2020 Jun 22, 2023	BUY	$26.57 - $51.74 $37,702 - $73,419	1,419 Added 35.67%	5,397 $143,000
Q3 2020 Jun 26, 2023	BUY	$26.5 - $55.4 $37,603 - $78,612	1,419 Added 35.67%	5,397 $266,000
Q3 2020 Mar 30, 2023	BUY	$26.5 - $55.4 $25,599 - $53,516	966 Added 21.8%	5,397 $266,000
Q3 2020 Nov 13, 2020	BUY	$26.5 - $55.4 $143,020 - $298,993	5,397 New	5,397 $267,000

Others Institutions Holding PCVX

# of Institutions

357

Shares Held

123M

Call Options Held

775K

Put Options Held

433K

Vanguard Group Inc Valley Forge, PA

11.4M
Shares

$1.05 Billion
0.02% of portfolio
Janus Henderson Group PLC London, X0

10.9M
Shares

$1 Billion
0.67% of portfolio
Black Rock Inc. New York, NY

9.94M
Shares

$914 Million
0.02% of portfolio
Ra Capital Management, L.P. Boston, MA

8.69M
Shares

$799 Million
13.83% of portfolio
Capital Research Global Investors Los Angeles, CA

4.9M
Shares

$450 Million
0.12% of portfolio

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.45B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account